Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
06 July 1965Website:
http://www.revvity.comNext earnings report:
31 January 2025Last dividends:
18 October 2024Next dividends:
17 January 2025Price
after hours | Thu, 21 Nov 2024 00:49:55 GMTAnalysts recommendations
Institutional Ownership
RVTY Latest News
Revvity's results for the third quarter show significant growth in their Diagnostics business, but there has been a drop in sales in the Life Sciences sector.
Revvity (RVTY) reported quarterly earnings of $1.28 per share, which is higher than the Zacks Consensus Estimate of $1.13 per share. This is an increase compared to earnings of $1.18 per share from the same period last year.
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) has announced its financial results for the third quarter ending September 29, 2024. The company reported earnings per share of $0.77, up from $0.08 during the same quarter last year. Additionally, GAAP revenue for this quarter was $684 million, compared to $671 million in the previous year, with an operating income of $98 million, rising from $69 million a year ago.
Revitty Incorporated (NYSE:RVTY) will hold its Q3 2024 earnings conference call on November 4, 2024, at 8:00 AM ET. The call will feature company leaders including Prahlad Singh, the CEO, and Max Krakowiak, the CFO, along with various participants from major financial institutions. The operator, Lydia, will welcome everyone to the call.
RVTY's results for the third quarter are expected to show good performance in the Diagnostics area, but the Life Sciences sector may continue to struggle in China.
RVTY has launched Transcribe AI, a tool that converts handwritten test request forms into digital format. This innovation speeds up workflows and minimizes mistakes in data entry.
Revvity's new solution for accurately typing the AD-related APOE gene may help evaluate a patient's risk of negative effects from new anti-amyloid treatments for Alzheimer's.
RVTY's ongoing commitment to innovation and a solid range of products creates a positive outlook for the stock.
RVTY has a solid range of products, which makes people feel positive about the stock.
Investors looking at Medical Services stocks probably know about Pediatrix Medical Group (MD) and Revvity (RVTY). However, which of these two stocks offers a better value opportunity for investors at this moment?
What type of business is Revvity?
Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
What sector is Revvity in?
Revvity is in the Healthcare sector
What industry is Revvity in?
Revvity is in the Diagnostics & Research industry
What country is Revvity from?
Revvity is headquartered in United States
When did Revvity go public?
Revvity initial public offering (IPO) was on 06 July 1965
What is Revvity website?
https://www.revvity.com
Is Revvity in the S&P 500?
Yes, Revvity is included in the S&P 500 index
Is Revvity in the NASDAQ 100?
No, Revvity is not included in the NASDAQ 100 index
Is Revvity in the Dow Jones?
No, Revvity is not included in the Dow Jones index
When was Revvity the previous earnings report?
No data
When does Revvity earnings report?
The next expected earnings date for Revvity is 31 January 2025